Animal Institute
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Elanco Animal Health Incorporated (Name of Registrant As Specified in Its Charter) (Name of Person(S) Filing Proxy Statement, If Other Than the Registrant)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Elanco Animal Health Incorporated (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: -
Case M.9554 - ELANCO ANIMAL HEALTH / BAYER ANIMAL HEALTH DIVISION
EUROPEAN COMMISSION DG Competition Case M.9554 - ELANCO ANIMAL HEALTH / BAYER ANIMAL HEALTH DIVISION Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) in conjunction with Art 6(2) Date: 08/06/2020 In electronic form on the EUR-Lex website under document number 32020M9554 EUROPEAN COMMISSION Brussels, 8.6.2020 C(2020) 3949 final PUBLIC VERSION In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. Elanco Animal Health Inc. 2500 Innovation Way 46140 Greenfield, Indiana United States of America Subject: Case M.9554 – Elanco Animal Health/Bayer Animal Health Division Commission decision pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation No 139/20041 and Article 57 of the Agreement on the European Economic Area2 Dear Sir or Madam, (1) On 14 April 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the “Merger Regulation”) by which Elanco Animal Health Inc. (“Elanco”, USA) acquires sole 1 OJ L 24, 29.1.2004, p. 1 (the "Merger Regulation"). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ("TFEU") has introduced certain changes, such as the replacement of "Community" by "Union" and "common market" by "internal market". -
Case No COMP/M.7277 - ELI LILLY/ NOVARTIS ANIMAL HEALTH
EN Case No COMP/M.7277 - ELI LILLY/ NOVARTIS ANIMAL HEALTH Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 03/10/2014 In electronic form on the EUR-Lex website under document number 32014M7277 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 3.10.2014 C(2014) 7228 final In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and MERGER PROCEDURE other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying party: Dear Sir / Madam, Subject: Case M.7277 – Eli Lilly/ Novartis Animal Health Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139 / 20041 (1) On 29 August 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Eli Lilly and Company ("Eli Lilly", United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Novartis Animal Health ("NAH", Switzerland) by way of purchase of shares and assets.2 Eli Lilly and NAH are collectively referred to as the "Parties". 1 OJ L 24, 29.1.2004, p. 1 ('the Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. -
Notice of Annual Meeting of Shareholders and Proxy Statement
Notice of Annual Meeting 2019 of Shareholders and Proxy Statement ELANCO ANIMAL HEALTH INCORPORATED 2500 Innovation Way Greenfield, Indiana 46140 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS May 8, 2019 The 2019 Annual Meeting of Shareholders of ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the “Company” or “Elanco”), will be a virtual meeting of shareholders, conducted via live audio webcast at www.virtualshareholdermeeting.com/ELAN2019 on Wednesday, May 8, 2019, at 8:00 a.m. Eastern Time (the “meeting”), to consider and act upon the following matters: Items of Business 1. Election of the four directors named in this proxy statement to serve three-year terms. 2. Ratification of the appointment of Ernst & Young LLP as the Company’s principal independent auditor for 2019. 3. Non-binding vote on the compensation of named executive officers. 4. Non-binding vote on the frequency of shareholder votes on the compensation of named executive officers. 5. Transaction of such other business as may properly come before the meeting. Voting Only shareholders of record at the close of business on March 22, 2019 are entitled to notice of, and to vote at, the meeting. At least five days prior to the meeting, a complete list of shareholders will be available for inspection by any shareholder entitled to vote at the meeting, during ordinary business hours, at the office of the Secretary of the Company at 2500 Innovation Way, Greenfield, Indiana 46140. You are cordially invited to participate in the annual meeting via live audio webcast and vote on the business items described in this proxy statement. -
Herbicide Company “Genealogy” February 2018
Herbicide Company “Genealogy” February 2018 The following chart is intended to show the history of the major U.S. herbicide companies. The information depends largely on people’s memories, which sometimes can be inexact, on records from the headquarters of major companies, and from histories on the internet. No guarantees are made for accuracy, although I think it is pretty close. The dates of the founding of companies or of acquisitions and mergers sometime vary slightly from one reference to another, so they should not be considered as solid historical facts. Only U.S. companies are listed. International companies are listed only if they had subsidiaries in the U.S., such as Bayer or BASF. I have tried to include mergers or acquisitions of entire companies or the ag divisions of companies, but acquisition of individual products are mentioned only occasionally. In many cases, the major company continues in existence and it is the agricultural division that becomes part of another company. Example: Aventis sold its ag products division to Bayer while the pharmaceutical portion of Aventis continues. Acquisitions of seed companies are not included. The major companies included are those with a history of synthesis, screening, and development of herbicides in the U.S., even if their parent company is overseas. This excludes marketing companies, post-patent distributors, and those companies dealing only with non-herbicide pesticides. Some companies have a distinguished herbicide history but no longer develop new herbicides. These are so noted. Numerous companies and individuals have been consulted and have been very helpful. But I have not always followed suggestions exactly if I felt I had more accurate information from a different source, so all the errors and omissions are mine.